Haemonetics (HAE) stock forecast for 2023. Forecast tables and graphs.

Haemonetics (HAE) stock forecast for 2023

Last update: September 27, 2023 (11:49)

Sector: Healthcare

The share price of Haemonetics Corporation (HAE) now

What analysts predict: $106.71
52-week High/Low: $95.26 / $72.19

50/200 Day Moving Average: $90.15 / $84.43

This figure corresponds to the Average Price over the previous 50/200 days. For Haemonetics stocks, the 50-day moving average is the resistance level today.

For Haemonetics stocks, the 200-day moving average is the resistance level today.

Are you interested in Haemonetics stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Haemonetics stock price in 2023. How much will one Haemonetics share be worth in 2023? Is it worth taking profit / loss on Haemonetics stock now or waiting? What are analysts' forecasts for Haemonetics stock?

We forecast Haemonetics stock performance using neural networks based on historical data on Haemonetics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. The Haemonetics stock prediction results are shown below and presented as a graph, table and text information.

Haemonetics stock forecasts are adjusted once a day based on the closing price of the previous trading day.

The minimum target price for Haemonetics analysts is $106.71.

Today 200 Day Moving Average is the support level (84.43 $).

50 Day Moving Average is the resistance level (90.15 $).





Historical and forecast chart of Haemonetics stock

The chart below shows the historical price of Haemonetics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Haemonetics stock price can be found in the table below.

Haemonetics (HAE) Forecast for 2023

Month Target Pes. Opt. Vol., %
Oct 89.03 84.85 91.88 7.66 %
Nov 89.39 87.16 96.01 9.22 %
Dec 89.39 82.86 93.77 11.63 %

Haemonetics information and performance

Haemonetics Corporation is a medical company offering hematology products and solutions. It operates through three segments: Plasma, Blood Center and Hospital. The company offers automated plasma collection devices, related disposable products and software, including NexSys PCS and PCS2 plasmapheresis equipment, as well as related disposable and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations and supply chain; and the NexLynk DMS Donor Management System.

Haemonetics Address

125 SUMMER STREET, BOSTON, MA, US

Market Capitalization: 4 614 792 000 $

Market capitalization of the Haemonetics Corporation is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of HAE shares in the company outstanding by the market price of one share.

EBITDA: 284 226 000 $

EBITDA of Haemonetics is earnings before interest, income tax and depreciation of assets.

PE Ratio: 34.21

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: 2.151

Price/earnings to growth

DPS: N/A

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: N/A

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: 2.66

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: 1.105
Quarterly Revenue Growth YOY: 0.191
Trailing PE: 34.21

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 25.45

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 4.333

Enterprise Value (EV) /Revenue

EV To EBITDA: 20.65

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 50712000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Haemonetics price target for 2023 by month


Target values for the price of one Haemonetics share for Oct 2023.

The weighted average target price per Haemonetics share in Oct 2023 is: 89.03.
In Oct, the Positive dynamics for Momo shares will prevail with possible monthly volatility of 7.655% volatility is expected.
Pessimistic target level: 84.85
Optimistic target level: 91.88

Target values for the price of one Haemonetics share for Nov 2023.

The weighted average target price per Haemonetics share in Nov 2023 is: 89.39.
In Nov, the Positive dynamics for Momo shares will prevail with possible monthly volatility of 9.218% volatility is expected.
Pessimistic target level: 87.16
Optimistic target level: 96.01

Target values for the price of one Haemonetics share for Dec 2023.

The weighted average target price per Haemonetics share in Dec 2023 is: 89.39.
In Dec, the Negative dynamics for Momo shares will prevail with possible monthly volatility of 11.630% volatility is expected.
Pessimistic target level: 82.86
Optimistic target level: 93.77



Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.